SEC Form 4Coverage since Aug 20, 2025Open-market trades only
$ROIV insider trading
Over the last 12 months, Roivant Sciences insiders reported 1 buy totaling $50K and 47 sales totaling $916.5M across SEC Form 4 filings. 40% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $50K 1 event
- Sold · 12m
- $916.5M 47 events
- Events · 12m
- 48 Form 4 filings, grouped
- Insiders · 12m
- 12 distinct reporters
- 10b5-1 share
- 40% of events, not dollars
Side
Price · $ROIV · 3Mvia TradingView
Top insiders · 12m
Venker EricPresident & Immunovant CEO14× · $109.2M
Sukhatme MayukhPresident & CIO6× · $109.1M
MANCHESTER KEITH S—5× · $154.5M
Fitzgerald Meghan—4× · $3.3M
Gold Daniel Allen—4× · $147.4M
All insider trades
50 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Epperly Melissa B,D | ▼ Sale | 4,938 | $39.74 | $196K | -33.3% | plan · 2 tranches |
| Sep 15, 2026 | Fitzgerald MeghanD | ▼ Sale | 5,112 | $39.74 | $203K | -12.4% | plan · 2 tranches |
| Sep 8, 2026 | Fitzgerald MeghanD | ▼ Sale | 20,000 | $39.9 | $798K | -31.8% | plan |
| Aug 28, 2026 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $35.77 | $7.2M | -11.1% | plan · 2 tranches |
| Aug 21, 2026 | Sukhatme MayukhPresident & CIO · O·D | ▼ Sale | 335,174 | $36.88 | $12.4M | -1.8% | 3 tranches |
| Aug 18, 2026 | Sukhatme MayukhPresident & CIO · O·D | ▼ Sale | 664,826 | $36.34 | $24.2M | -3.4% | 4 tranches |
| Jul 27, 2026 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $34.95 | $7.0M | -11% | plan |
| Jun 30, 2026 | Fitzgerald MeghanD | ▼ Sale | 10,000 | $34.9 | $349K | -18.9% | plan |
| Jun 30, 2026 | MANCHESTER KEITH SD | ▼ Sale | 200,000 | $35.45 | $7.1M | -10.3% | — |
| Jun 30, 2026 | MANCHESTER KEITH SD | ▼ Sale | 1,438,163 | $34.32 | $49.4M | -9.5% | 5 tranches · indirect |
| Jun 30, 2026 | Gold Daniel AllenD | ▼ Sale | 1,438,163 | $34.32 | $49.4M | -9.5% | 5 tranches · indirect |
| Jun 30, 2026 | QVT Financial LP | ▼ Sale | 1,438,163 | $34.32 | $49.4M | -9.5% | 5 tranches · indirect |
| Jun 29, 2026 | Epperly Melissa B,D | ▼ Sale | 17,750 | $34.38 | $610K | -51.9% | plan · 2 tranches |
| Jun 26, 2026 | Sukhatme MayukhPresident & CIO · O·D | ▼ Sale | 1,000,000 | $34.1 | $34.1M | -5.1% | 2 tranches |
| Jun 24, 2026 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $33.16 | $6.6M | -11% | plan · 2 tranches |
| Apr 20, 2026 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $29.59 | $5.9M | -10.8% | plan |
| Apr 16, 2026 | Gline MatthewCEO · O·D | ▼ Sale | 289,774 | $29.16 | $8.4M | -1.7% | — |
| Apr 8, 2026 | Humes JenniferChief Accounting Officer · O | ▼ Sale | 13,538 | $28.37 | $384K | -13.9% | — |
| Mar 26, 2026 | Fitzgerald MeghanD | ▼ Sale | 70,000 | $27.45 | $1.9M | -62% | — |
| Mar 17, 2026 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $28.24 | $5.6M | -10.8% | plan |
| Mar 16, 2026 | Epperly Melissa B,D | ▼ Sale | 41,861 | $28.68 | $1.2M | -72.6% | — |
| Feb 23, 2026 | Torti FrankPresident and Vant Chair · O | ▼ Sale | 3,000,000 | $27.35 | $82.0M | -17.9% | plan · 3 tranches |
| Feb 13, 2026 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $26.49 | $5.3M | -10.8% | plan |
| Feb 13, 2026 | MANCHESTER KEITH SD | ▼ Sale | 1,225,784 | $26.64 | $32.7M | -7.5% | 5 tranches · indirect |
| Feb 13, 2026 | Gold Daniel AllenD | ▼ Sale | 1,225,784 | $26.64 | $32.7M | -7.5% | 5 tranches · indirect |
| Feb 13, 2026 | QVT Financial LP | ▼ Sale | 1,225,784 | $26.64 | $32.7M | -7.5% | 5 tranches · indirect |
| Feb 9, 2026 | Sukhatme MayukhPresident & CIO · O·D | ▼ Sale | 339,441 | $26.47 | $9.0M | -1.7% | — |
| Jan 12, 2026 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $21.92 | $4.4M | -10.8% | plan |
| Dec 31, 2025 | Sukhatme MayukhPresident & CIO · O·D | ▼ Sale | 1,330,868 | $21.72 | $28.9M | -6.2% | 2 tranches |
| Dec 24, 2025 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 275,000 | $22.47 | $6.2M | -14.3% | 2 tranches |
| Dec 23, 2025 | Pulik RichardCFO · O | ▼ Sale | 406,731 | $22.43 | $9.1M | -62.9% | late · 2 tranches |
| Dec 17, 2025 | Sukhatme MayukhPresident & CIO · O·D | ▼ Sale | 26,831 | $23.09 | $620K | -0.1% | — |
| Dec 17, 2025 | Gold Daniel AllenD | ▼ Sale | 1,694,614 | $23.05 | $39.1M | -9.4% | 5 tranches · indirect |
| Dec 17, 2025 | MANCHESTER KEITH SD | ▼ Sale | 1,694,614 | $23.05 | $39.1M | -9.4% | 5 tranches · indirect |
| Dec 17, 2025 | QVT Financial LP | ▼ Sale | 1,694,614 | $23.05 | $39.1M | -9.4% | 5 tranches · indirect |
| Dec 15, 2025 | Gline MatthewCEO · O·D | ▼ Sale | 1,740,000 | $21.68 | $37.7M | -8.5% | 3 tranches |
| Dec 15, 2025 | Ramaswamy Vivek10% | ▼ Sale | 3,103,745 | $21.89 | $67.9M | -8.3% | 3 tranches |
| Dec 9, 2025 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $20.85 | $4.2M | -11.8% | plan |
| Nov 19, 2025 | MANCHESTER KEITH SD | ▼ Sale | 1,300,000 | $20.23 | $26.3M | -6.7% | 4 tranches · indirect |
| Nov 19, 2025 | Gold Daniel AllenD | ▼ Sale | 1,300,000 | $20.23 | $26.3M | -6.7% | 4 tranches · indirect |
| Nov 19, 2025 | QVT Financial LP | ▼ Sale | 1,300,000 | $20.23 | $26.3M | -6.7% | 4 tranches · indirect |
| Nov 17, 2025 | Ramaswamy Vivek10% | ▼ Sale | 1,854,603 | $20.46 | $37.9M | -5.2% | 3 tranches |
| Nov 7, 2025 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 200,000 | $20.22 | $4.0M | -11.7% | plan |
| Oct 17, 2025 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 851,383 | $16.99 | $14.5M | -36.1% | plan · 3 tranches |
| Oct 13, 2025 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 125,667 | $16.29 | $2.0M | -7.7% | plan · 2 tranches |
| Oct 8, 2025 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 665,159 | $16.21 | $10.8M | -30.7% | plan · 3 tranches |
| Sep 23, 2025 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 1,711,000 | $14.92 | $25.5M | -53.2% | plan · 4 tranches |
| Sep 18, 2025 | Gline MatthewCEO · O·D | ▲ Buy | 3,315 | $15.07 | $50K | — | — |
| Sep 5, 2025 | Ramaswamy Vivek10% | ▼ Sale | 1,775,749 | $12.65 | $22.5M | -4.8% | 3 tranches |
| Aug 20, 2025 | Venker EricPresident & Immunovant CEO · O | ▼ Sale | 100,000 | $11.72 | $1.2M | -5.7% | plan |
Every $ROIV filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Roivant Sciences filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ROIV feed.